FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/02/079996 [Registered on: 06/02/2025] Trial Registered Prospectively
Last Modified On: 23/05/2025
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Dentistry 
Study Design  Randomized, Parallel Group, Placebo Controlled Trial 
Public Title of Study   To find the effect of Gurunanda Oil Pulling Oral Rinse with Ashwagandha & Neem in reducing teeth Sensitivity 
Scientific Title of Study   A Randomized, Multi-centric, Double blinded three arm, Placebo and Active Controlled parallel group comparative clinical trial to assess the efficacy and safety of Gurunanda Oil Pulling Oral Rinse with Ashwagandha & Neem in reducing the sensitivity of teeth and gums. 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
GNASHWAGANDAOIL/32/24 Ver 1.0  Protocol Number 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
Modification(s)  
Name  Dr Aravindhan R Ph.D 
Designation  Associate professor 
Affiliation  SRM Medical College Hospital and Research Centre 
Address  Room No 1, Department of Oral & Maxillofacial Pathology SRM Kattankulathur dental college SRMIST, KattanKulathur, Chennai

Kancheepuram
TAMIL NADU
603203
India 
Phone  9790801260  
Fax    
Email  aravindhandr@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr M Sakthi Balan MD 
Designation  Consultant Diabetologist and CI 
Affiliation  KI3 PRIVATE LIMITED 
Address  No. 5/3,Jayalakshmi Street, Radha Nagar, Chromepet, Chennai- 600 044 Tamil Nadu, India.

Chennai
TAMIL NADU
600044
India 
Phone  9443627722  
Fax    
Email  saheerose@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Gayathri Sivakumar 
Designation  Director 
Affiliation  KI3 PRIVATE LIMITED 
Address  No. 5/3,Jayalakshmi Street, Radha Nagar, Chromepet, Chennai- 600 044 Tamil Nadu, India.

Chennai
TAMIL NADU
600044
India 
Phone  9003109416  
Fax    
Email  drgayathri@ki3services.com  
 
Source of Monetary or Material Support  
GuruNanda LLC 6645 Caballero Blvd, Buena Park, CA 90620  
 
Primary Sponsor  
Name  Gurunanda LLC 
Address  6645 Caballero Blvd, Buena Park, CA 90620  
Type of Sponsor  Pharmaceutical industry-Global 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 2  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr R C Satish Kumar   SRM Medical College Hospital and Research Centre   Dept. of Oral Pathology, SRM Medical College Hospital and Research Centre Chennai
Kancheepuram
TAMIL NADU 
9884845887

ayurbheshaja@gmail.com 
Dr Madhushriee Venkatesan  Vinayaka Missions Sankarachariyar Dental College   Room No 1, Sankari Main Road (NH-47) Ariyanoor, Salem - 636308 Tamil Nadu, India Salem
Kancheepuram
TAMIL NADU 
9740575508

drmadhushriee@vmsdc.edu.in 
 
Details of Ethics Committee  
No of Ethics Committees= 2  
Name of Committee  Approval Status 
Institutional Ethics Committee   Approved 
Institutional Ethics Committee   Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: K088||Other specified disorders of teethand supporting structures,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Gurunanda Oil Pulling Oral Rinse with Ashwagandha & Neem  Caprylic/Capric/Lauric Triglyceride, Cinnamon Oil, Ashwagandha Extract, Clove Oil, Cardamom Oil, Tea Tree Oil, Turmeric Extract, Roman Chamomile Oil, Vitamin E, Vitamin D3, Oregano Oil, Stevia Leaf Extract, Vitamin K2, Neem Extract Usage: 10 mL once a day. Rinse for at least 2 minutes. 
Comparator Agent  Listerine Sensitivity Mouthwash  Water, Sorbitol, Propylene Glycol, Dipotassium Oxalate Monohydrate, Flavor, Phosphoric Acid, Poloxamer, Sodium Benzoate, Sodium Methyl Cocoyl Taurate, Sodium Lauryl Sulfate, Sucralose, Sodium Saccharin Directions Use twice-daily after brushing After brushing, rinse mouth with water before use Pour 2 teaspoonfuls (10 mL) into a cup, rinse for 60 seconds, then spit out Do not exceed the recommended twice per day dose of 2 teaspoonfuls (10 mL) Do not dilute, swallow 
Comparator Agent  Placebo Rinse (Purified Water, Glycerin, Propanediol, Xylitol, PEG Hydrogenated Castor Oil, Sodium Benzoate, Flavor, Citric Acid, Sucralose)  Shake well. Place 10 ml of Oral Rinse in mouth. Gently swish between teeth for at least 2 minutes. Spit out and rinse mouth thoroughly with water. DO NOT SWALLOW.Always brush your teeth after using oil pulling. To be used twice daily for 4 weeks  
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  60.00 Year(s)
Gender  Both 
Details  1. Participants aged 18 to 50 years.
2. Presence of a minimum of 20 teeth.
3.Presence of tooth sensitivity (index of the intensity of teeth hyperesthesia, IIGZ score greater than 2).
4.Adequate oral hygiene and no signs of oral neglect.
5. Qualifying response to the Air Blast stimuli as defined by a score of 2 or 3 on the Schiff Cold Air Sensitivity Scale.
6. Use of a non-desensitizing dentifrice for one month prior to entry into the study.
Participant is willing to provide informed consent and is willing to participate in all procedures and follow up evaluations necessary to complete the study
7. 
 
ExclusionCriteria 
Details  1. Professional teeth cleaning and whitening less than 30 days before the examination.
2. Carrying out other dental procedures, including orthodontic and surgical, less than 30 days prior to the study, or the need to carry out them during the study period.
3. The use of analgesic agents less than 7 days prior to inclusion.
4. Untreated dental caries or active periodontal disease
5. Presence of cracked, chipped, or fractured teeth.
6. Severe enamel loss, dentin exposure, or pulpitis
7. Teeth whitening, scaling, or polishing within the past 4–6 weeks.
8. Recent restorations or oral surgeries that could influence sensitivity.
9. Regular use of desensitizing toothpaste or treatments within the past 4 weeks
10. Use of prescription fluoride treatments or other dental products specifically targeting sensitivity
11. Conditions affecting oral health, such as diabetes, Sjögren’s syndrome, or GERD
12. Excessive consumption of acidic foods or beverages
13. Heavy tobacco or alcohol use that could affect oral health or study results.
14. History of bruxism, clenching, or other habits that could increase tooth wear.
15. Known allergies to any components of the products being tested.

16. Conditions or medications that might interfere with the perception of sensitivity (e.g., pain medications)
17. Participation in any other clinical study or test panel within one month prior to entry into the study.
18. History of Hepatitis B or C, HIV infection.
19. Chemotherapy, radiation therapy or cytokine therapy less than 5 years before being included in the study
20. Pregnant or lactating participants. 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Pharmacy-controlled Randomization 
Blinding/Masking   Participant and Investigator Blinded 
Primary Outcome  
Outcome  TimePoints 
1.Objective assessment of the sensitivity of hard tooth tissue, an index of the intensity of teeth hyperesthesia (IIGZ) will be used
2.A visual analogue scale is proposed for self-assessment by the participant of the level of pain in the samples, where the values from 1 to 3 corresponded to the light intensity of pain, from 4 to 6 points - moderate, and 7 or higher – strong
3.To evaluate the cleaning effect of studied products Oral Hygiene Index Simplified (OHI-S) [ Time Frame: Baseline to 4 weeks]
4. Air Blast Hypersensitivity [ during each visit over 1-4 weeks]
5. Examiner rates the response to stimulation of hypersensitive teeth using a jet of air (constant stimulus based on duration, pressure, temperature, distance from target). Response is rated based on the Schiff Cold Air Sensitivity Scale.
6. Reductions in extrinsic tooth stain area and extrinsic tooth stain intensity.
7. Photographic Assessment 
Baseline,Week 1, Week 2 , Week 3 and Week 4 
 
Secondary Outcome  
Outcome  TimePoints 
Participant and Investigator Feedback will be obtained before enrollment and after completion of the study
Adverse event monitoring 
Baseline,Week 1, Week 2 , Week 3 and Week 4 
 
Target Sample Size   Total Sample Size="90"
Sample Size from India="90" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 3 
Date of First Enrollment (India)   06/02/2025 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="0"
Months="10"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary   The participants will be sequentially and randomly assigned the groups according to the computer -generated code.

Group 1- 30 subjects- GuruNanda Oil Pulling Oral Rinse with Ashwagandha and Neem, once daily for 4 weeks

Group 2- 30 subjects- Listerine Sensitivity Mouhtwash

Group 3- 30 subjects- Placebo Oral Rinse 

Primary  Outcome

1) Objective Assessment of the sensitivity of hard tooth tissue, an index of the intensity of teeth hyperesthesia (IIGZ) 
2) A Visual Analogue scale is proposed for self-assessment by the participant of the level of pain in the samples
3) To evaluate the cleaning effect of studied products Oral Hygiene Index Simplified (OHI-S)
4) Air Blast Hypersensitivity (Baseline to 4 weeks)
5) Reductions in extrinsic tooth stain area and extrinsic tooth stain intensity
6) Photographic Assessment of dental Hygiene

Secondary Outcome
1) Participant and Investigator Feedback 
2) Adverse event monitoring 
 
Close